Heartflow, Inc. (HTFL)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Cardiovascularsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 16/100 (LOW), 25.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 10.28% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- AI Cardiac Diagnostics Pioneer Sets HeartFlow (HTFL) for High-Margin Expansion
- BCSM Exits Heartflow (HTFL) on Competitive Concerns
- HeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week High
- HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High
- Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
- HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?
- Heartflow (HTFL) Rockets 46%: What Analysts Say and Where Hedge Funds Stand
- HeartFlow (HTFL) Jumps On Q2 Results As Raised Outlook Leaves Shares Fully Valued
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Heartflow, Inc..
Full HTFL Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.